皮膚用抗感染 燙傷藥膏 prevention and treatment of infection particularly by Pseudomonas aeruginosa; severe burns.

Silver sulfadiazine is a synthetic anti-infective agent produced by the reaction of silver nitrate with sulfadiazine.

Silver sulfadiazine itself does not appear to be absorbed. When the drug is applied to extensive burns, serum sulfadiazine concentrations of up to 12 mg/dL have been reported.

Because sulfonamide therapy is known to increase the possibility of kernicterus, do not used in pregnancy women near term or in newborn infants. Do not use in Glucose-6-phosphate dehydrogenase deficient individual. Also should not be used with proteolytic enzymes.

There are no adequate and controlled studies to date using silver sulfadiazine in pregnant women, and the drug should be used during pregnancy only when clearly needed. The drug is not recommended for use in pregnant women unless the burned area covers more than 20% of the body surface or the therapeutic benefits to the patient outweigh the possible risks to the fetus. Because sulfonamide therapy has produced kernicterus in neonates, silver sulfadiazine cream is contraindicated in pregnant women approaching or at term.

It is not known whether silver sulfadiazine is distributed into human milk. Because sulfonamides are distributed into milk and sulfonamides may cause kernicterus in infants younger than 2 months of age, silver sulfadiazine should be used with caution in nursing women.

Pain, burning, or itching have occasionally been reported following application of silver sulfadiazine cream

The burn wounds are cleaned and debrided and silver sulfadiazine is applied to a thickness of 3 to 5 mm with a sterile gloved hand, once to twice daily.